DLL3 and neoplasm: There is considerable interest in the development of targeted therapies against DLL3, including antibody–drug conjugates (ADCs) and engineered T cell therapies (e.g., chimeric antigen receptor T), both relying on the selective expression of DLL3 in cancer cells, allowing the targeted delivery of therapeutic agents directly to the tumor.